These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33550042)

  • 1. The emerging roles of IDO2 in cancer and its potential as a therapeutic target.
    Li P; Xu W; Liu F; Zhu H; Zhang L; Ding Z; Liang H; Song J
    Biomed Pharmacother; 2021 May; 137():111295. PubMed ID: 33550042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Challenges for IDO2 as Target in Cancer Immunotherapy.
    Mondanelli G; Mandarano M; Belladonna ML; Suvieri C; Pelliccia C; Bellezza G; Sidoni A; Carvalho A; Grohmann U; Volpi C
    Front Immunol; 2021; 12():679953. PubMed ID: 33968089
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
    Fatokun AA; Hunt NH; Ball HJ
    Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
    Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
    Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
    Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
    Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
    Front Immunol; 2021; 12():789473. PubMed ID: 34938297
    [No Abstract]   [Full Text] [Related]  

  • 8. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.
    Ball HJ; Yuasa HJ; Austin CJ; Weiser S; Hunt NH
    Int J Biochem Cell Biol; 2009 Mar; 41(3):467-71. PubMed ID: 18282734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1.
    Pantouris G; Serys M; Yuasa HJ; Ball HJ; Mowat CG
    Amino Acids; 2014 Sep; 46(9):2155-63. PubMed ID: 24875753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heme-containing enzymes and inhibitors for tryptophan metabolism.
    Yan D; Lin YW; Tan X
    Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy.
    Austin CJ; Rendina LM
    Drug Discov Today; 2015 May; 20(5):609-17. PubMed ID: 25478733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
    Röhrig UF; Majjigapu SR; Caldelari D; Dilek N; Reichenbach P; Ascencao K; Irving M; Coukos G; Vogel P; Zoete V; Michielin O
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4330-3. PubMed ID: 27469130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.
    Liu Y; Zhang Y; Zheng X; Zhang X; Wang H; Li Q; Yuan K; Zhou N; Yu Y; Song N; Fu J; Min W
    Oncotarget; 2016 May; 7(22):32329-40. PubMed ID: 27058624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase 2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma.
    Yamasuge W; Yamamoto Y; Fujigaki H; Hoshi M; Nakamoto K; Kunisawa K; Mouri A; Nabeshima T; Saito K
    Cancer Sci; 2019 Oct; 110(10):3061-3067. PubMed ID: 31444833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.
    Austin CJ; Mailu BM; Maghzal GJ; Sanchez-Perez A; Rahlfs S; Zocher K; Yuasa HJ; Arthur JW; Becker K; Stocker R; Hunt NH; Ball HJ
    Amino Acids; 2010 Jul; 39(2):565-78. PubMed ID: 20140689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
    Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
    Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
    Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
    Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.